Table 4.
Changes in clinical parameters of the included studies
|
Intervention
|
Clinical parameters evaluated
|
||||||||||
|
|
Ref.
|
Creatinine (mg/dL)
|
Change in BUN (mg/dL)
|
Cystatin C (mg/L)
|
GFR (mL/min)
|
Urine output (mL/d)
|
|||||
|
Baseline
|
72 h
|
Baseline
|
72 h
|
Baseline
|
72 h
|
Baseline
|
72 h
|
Baseline
|
72 h
|
||
| Levosimendan | Fedele et al[12], 2014 | 1.76 ± 0.37 | 1.51 ± 0.5 | 45.08 ± 22.19 | 33.14 ± 16.63 | 2577.5 ± 700.6 | 2083 ± 731.4 | 38.71 ± 7.94 | 53.34 ± 14.93 | 1766.4 ± 514.2 | 2663.5 ± 721.2 |
| Fedele et al[12], 2014 (placebo) | 1.6 ± 0.2 | 1.7 ± 0.2 | 44.4 ± 13.1 | 47 ± 12.8 | 2498.5 ± 262 | 2470 ± 409.9 | 43.33 ± 7.99 | 40.24 ± 6.58 | 1571.4 ± 125.3 | 1778.51 ± 798.1 | |
| Ref. | Creatinine (mg/dL) | Change in BUN (mg/dL) | RBF (mL/min) | GFR (mL/min) | FF | ||||||
| Baseline | Treatment | Baseline | Treatment | Baseline | Treatment | Baseline | Treatment | Baseline | Treatment | ||
| Inomata et al[14], 2017 | NA | NA | NA | NA | 426 ± 197 | 518 ± 276 | 36.5 ± 18.3 | 44.5 ± 19.0 | 0.146 ± 0.080 | 0.143 ± 0.069 | |
BUN: Blood urea nitrogen; FF: filtration fraction; GFR: glomerular filtration rate; NA: Not available; RBF: renal blood flow.